GLPwatch
Mounjaro for Parkinson's disease
tirzepatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCMounjaro (tirzepatide) is not FDA-approved for Parkinson's disease, and any use for this condition is off-label or investigational. Research in animal models suggests tirzepatide may have neuroprotective effects in Parkinson's disease, but these findings have not been confirmed in humans.
AI summary of the sources below.
| Drug | Mounjaro (tirzepatide) |
|---|---|
| Condition | Parkinson's disease |
| Approval status | Investigational / off-label |
| Research papers | 4 |
Mounjaro is not FDA-approved for parkinson's disease; the research below reflects investigational or off-label study only.
Research on tirzepatide for parkinson's disease (4)
- Tirzepatide prevents neurodegeneration through multiple molecular pathways.
- Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases.
- Dual GLP-1 and GIP Agonist Tirzepatide Exerted Neuroprotective Action in a Parkinson's Disease Rat Model.
- GLP-1/GIP dual agonist tirzepatide alleviates mice model of Parkinson's disease by promoting mitochondrial homeostasis.